Fig. 5: PK/PD evaluation of PVTX-405 in immune-competent and gene-edited C57BL/6 mice harboring humanized CrbnI391V gene. | Nature Communications

Fig. 5: PK/PD evaluation of PVTX-405 in immune-competent and gene-edited C57BL/6 mice harboring humanized CrbnI391V gene.

From: Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy

Fig. 5

CrbnI391V mice were administered with vehicle control or PVTX-405 via oral gavage using 100% PEG200 as the dosing vehicle. Mice were sacrificed at indicated time-points, and blood samples, spleen tissues and thymus tissues were harvested for analysis. At each time point, 4 mice were euthanized for each dosing group. a IKZF2 degradation induced by PVTX-405 in spleen and thymus tissues in mice. A method of one-way ANOVA was used for P value calculation: “**”P < 0.01; “****”P < 0.0001. The p values for all PVTX-405 treated groups compared with their corresponding vehicle control are <0.0001, except a p value of 0.0088 for the group (10 mg/kg PVTX-405, Thymus, 24 h) compared with the vehicle control of thymus tissue. Data presented as mean ± SEM, with n = 4 animals for each treatment group. b Concentrations of PVTX-405 in plasma, spleen and thymus at 6, 12, and 24 h time-points and 10, 30, and 100 mg/kg doses. “ND”: not determined. Data presented as mean ± SEM, with n = 4 animals for each treatment group. Source data are provided as a Source Data file.

Back to article page